Article

New Evidence, New Treatments: The Impact of Clinical Trials on GlaucomaManagement

Chicago-The decision of whether to treat glaucoma or ocular hypertensionshould be a mutual one reached by both ophthalmologist and patient. Thedecision should take into account the risk of visual loss as the resultof glaucoma over the patient's lifetime and the potential treatment benefits.The risk factors that are most important in deciding whether to treat patientsinclude the level of IOP, race, age, and family history of glaucoma. KuldevSingh, MD, discussed the individualized approach to patient treatment andall factors that need to be considered.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.